Compare · BCDA vs BIIB
BCDA vs BIIB
Side-by-side comparison of BioCardia Inc. (BCDA) and Biogen Inc. (BIIB): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both BCDA and BIIB operate in Biotechnology: Biological Products (No Diagnostic Substances) (Health Care), so they compete in similar markets.
- BIIB is the larger of the two at $29.85B, about 3087.1x BCDA ($9.7M).
- Over the past year, BCDA is down 62.4% and BIIB is up 56.3% - BIIB leads by 118.8 points.
- BCDA has been more active in the news (13 items in the past 4 weeks vs 11 for BIIB).
- BIIB has more recent analyst coverage (25 ratings vs 1 for BCDA).
- Company
- BioCardia Inc.
- Biogen Inc.
- Price
- $0.85-3.45%
- $202.19+0.81%
- Market cap
- $9.7M
- $29.85B
- 1M return
- -20.65%
- +1.23%
- 1Y return
- -62.42%
- +56.35%
- Industry
- Biotechnology: Biological Products (No Diagnostic Substances)
- Biotechnology: Biological Products (No Diagnostic Substances)
- Exchange
- NASDAQ
- NASDAQ
- IPO
- News (4w)
- 13
- 11
- Recent ratings
- 1
- 25
BioCardia Inc.
BioCardia, Inc., a clinical-stage regenerative medicine company, develops therapeutics for cardiovascular diseases. Its lead therapeutic candidate is the CardiAMP Cell Therapy System for the treatment of heart failure and chronic myocardial ischemia; and ALLOGENEIC cell therapy for cardiac and pulmonary disease. The company is also developing ALLOGENEIC Cell Therapy System, an investigational culture expanded bone marrow derived mesenchymal cell therapy, which is in Phase I/II trial for the treatment of ischemic systolic heart failure. In addition, it offers the Helix biotherapeutic delivery system, a percutaneous catheter delivery system for cardiovascular regenerative medicine; and Morph deflectable guides and sheaths. The company is based in San Carlos, California.
Biogen Inc.
Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases. The company offers TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; and FUMADERM to treat plaque psoriasis. It also provides BENEPALI, an etanercept biosimilar referencing ENBREL; IMRALDI, an adalimumab biosimilar referencing HUMIRA; and FLIXABI, an infliximab biosimilar referencing REMICADE. In addition, the company offers RITUXAN for treating non-Hodgkin's lymphoma, chronic lymphocytic leukemia (CLL), rheumatoid arthritis, two forms of ANCA-associated vasculitis, and pemphigus vulgaris; RITUXAN HYCELA for non-Hodgkin's lymphoma and CLL; GAZYVA to treat CLL and follicular lymphoma; and OCREVUS for treating relapsing MS and primary progressive MS; and other anti-CD20 therapies. Further, it develops BIIB061, BIIB091, and BIIB107 for MS and neuroimmunology; Aducanumab, BAN2401, BIIB092, BIIB076, and BIIB080 to treat Alzheimer's disease and dementia; BIIB067, BIIB078, BIIB105, BIIB100, and BIIB110 to treat neuromuscular disorders; BIIB124, BIIB094, BIIB118, BIIB101, and BIIB122 for treating Parkinson's disease and movement disorders; BIIB111 and BIIB112 to treat ophthalmology related diseases; BIIB125 and BIIB104 for treating neuropsychiatry; Dapirolizumab pegol and BIIB059 to treat immunology related diseases; BIIB093 and TMS-007 to treat acute neurology; BIIB074 and BIIB095 for neuropathic pain; and SB11 and SB15 biosimilars, which are under various stages of development. The company has collaboration and license agreements with Acorda Therapeutics, Inc.; Alkermes Pharma Ireland Limited; Bristol-Myers Squibb Company; Eisai Co., Ltd.; Genentech, Inc.; Neurimmune SubOne AG; Ionis Pharmaceuticals, Inc.; Ginkgo Bioworks; Capsigen Inc.; and Mirimus, Inc. Biogen Inc. was founded in 1978 and is headquartered in Cambridge, Massachusetts.
Latest BCDA
- President and CEO Altman Peter bought $415 worth of shares (500 units at $0.83), increasing direct ownership by 0.14% to 368,885 units (SEC Form 4)
- President and CEO Altman Peter bought $3,754 worth of shares (4,300 units at $0.87), increasing direct ownership by 1% to 368,385 units (SEC Form 4)
- President and CEO Altman Peter bought $7,175 worth of shares (7,500 units at $0.96), increasing direct ownership by 2% to 369,485 units (SEC Form 4)
- President and CEO Altman Peter bought $5,208 worth of shares (5,400 units at $0.96), increasing direct ownership by 2% to 361,985 units (SEC Form 4)
- SEC Form 4 filed by Director Stertzer Simon H
- SEC Form 4 filed by Director Slosman Marvin
- President and CEO Altman Peter covered exercise/tax liability with 54,606 shares, decreasing direct ownership by 13% to 356,585 units (SEC Form 4)
- Chief Financial Officer Mcclung David covered exercise/tax liability with 23,125 shares, decreasing direct ownership by 17% to 114,245 units (SEC Form 4)
- Senior Vice President, Devices Gillis Edward M covered exercise/tax liability with 17,269 shares, decreasing direct ownership by 24% to 54,126 units (SEC Form 4)
- SEC Form 4 filed by Director Blank Andrew Scott
Latest BIIB
- Synapticure Launches Groundbreaking Ataxia Care Program, Expanding Access to Specialized Neurology Nationwide
- Biogen Appoints Michael J. Parini as Chief Legal Officer
- LEQEMBI® Real-World LEADER Study Presented at AAIC® 2026 Finds Over 75% of Early Alzheimer’s Patients Enrolled in the Study Remained Stable and Nearly 7% Improved Over an Average of 17 Months of Treatment
- LEQEMBI® Real-World LEADER Study Presented at AAIC® 2026 Finds Over 75% of Early Alzheimer's Patients Enrolled in the Study Remained Stable and Nearly 7% Improved Over an Average of 17 Months of Treatment
- Biogen Presents Phase 2 CELIA Data at AAIC Demonstrating Meaningful Clinical Outcomes and Robust Tau Reduction with Diranersen in Early Alzheimer’s Disease
- FDA Approves LEQEMBI IQLIK® (lecanemab-irmb) Subcutaneous Injection as an Initiation Dose for Early Alzheimer’s Disease
- FDA Approves LEQEMBI IQLIK® (lecanemab-irmb) Subcutaneous Injection as an Initiation Dose for Early Alzheimer's Disease
- Biogen upgraded by Truist with a new price target
- Stoke Therapeutics Appoints Thomas McCauley, Ph.D., as Chief Scientific Officer
- LEQEMBI® Subcutaneous Autoinjector Clinical Data Supports Similar Efficacy and Safety to IV Formulation in Early Alzheimer’s Disease Presented at the Alzheimer’s Association International Conference® (AAIC®) 2026